Mesoblast is committed to bring to market its disruptive cellular medicines to treat serious and life-threatening illnesses.

Our Product Candidates

We have leveraged our proprietary technology platforms based on specialized cells known as mesenchymal lineage adult stem cells (MLCs) to establish what we believe is the most advanced cellular medicines portfolio in the industry.

Our ‘off-the-shelf’ products are allogeneic — meaning cells from one donor may be used in many different recipients without the need for matching.

Our licensee in Japan has received full approval for the first allogeneic cell-based product in Japan based on our MLC technology. 

We believe we are well positioned to have the first industrially manufactured allogeneic mesenchymal lineage cell-based product approved in the United States.

Our lead product candidates under investigation are:

  • MPC-150-IM for chronic heart failure
  • MPC-06-ID for chronic low back pain due to disc degeneration
  • MSC-100-IV for acute graft versus host disease
  • MPC-300-IV for biologic refractory rheumatoid arthritis and diabetic nephropathy

We also have a strong emerging pipeline of products for follow-on indications.